The legislation was written to reauthorize the FDA’s prescription drug user fee program, which allows the organization to collect fees from drug manufacturers. The Act also includes incentives to pursue antibiotic research and development and calls for the use of antimicrobial stewardship programs to protecting existing antibiotics.
Title X of the bill includes provisions to help prevent drug shortages, including a requirement that manufacturers notify the FDA when the production of certain drugs would be interrupted and a requirement that the Drug Enforcement Administration provides timely updates on drug quota increases to manufacturers.
The House approved the Act last week, and the president is expected to sign it into law in the days ahead.
Related Articles on Anesthesia:
Study: Overweight Patients Receive Excessive Neuromuscular Blockers
Study: Disposable Acupressure Device Reduces Post-Op Nausea
9 Anesthesiologist Appointments and Accomplishments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
